The inhibition constant (Ki) of every compound was determined from the Cheng-Prusoff equation: Ki?=?IC50/(1?+?[L]/Kd), where IC50 may be the concentration of substance that displaces the binding of radioligand by 50%, [L] may be the free of charge concentration of radioligand, and Kd may be the dissociation regular of every radioligand

The inhibition constant (Ki) of every compound was determined from the Cheng-Prusoff equation: Ki?=?IC50/(1?+?[L]/Kd), where IC50 may be the concentration…

Continue Reading →

The described therapeutic tools that specifically target human CCR9+-tumors and have been tried in xenogeneic models are limited to the use of the CCR9-ligand coupled to a cytotoxic agent (CCL25-PE38 fusion protein) (33), the use of ligand-specific antibodies, alone or in combination with etoposide (25), or the mAb 91R that selectively inhibited growth of a human acute T lymphoblastic leukemia (T-ALL) cell line in Rag2?/? xenografts (34)

The described therapeutic tools that specifically target human CCR9+-tumors and have been tried in xenogeneic models are limited to the…

Continue Reading →